Abstract:ABSTRACT Developing broad-spectrum vaccines and optimal vaccination strategies is crucial to controlling the COVID-19 pandemic. Here, we generated a chimpanzee adenoviral vector-based COVID-19 vaccine carrying broad-spectrum immunogens, modified full-length spike, and conserved T-cell epitopes of SARS-CoV-2, and assessed its immune response in mice through intramuscular (i.m.), intranasal (i.n.), or combined immunization routes (i.m. + i.n., or i.n. + i.m.). Compared to other vaccination strategies, the two combined regimens elicited higher neutralizing antibody (NAb) responses to all variants. Compared to i.n. + i.m. regimen, the i.m. + i.n. regimen stimulated a stronger secondary GC response, which is more pivotal to high-quality antibody production than the primary GC response. Moreover, the i.m. + i.n. regimen was adept at mediating systemic cellular immunity, while the i.n. + i .m. regimen tended to elicit lung tissue-resident memory T (T RM ) cell responses. Overall, the two combined regimens induced comprehensive but distinct immune responses consisting of lgA, lgG, NAbs, GC B cells, long-lived plasma cells, T RM cells, and systemic memory T cells, which conferred complete protection against BA.2 infection in hACE2 transgenic mice, and warranted further investigation as potential universal vaccination strategies. IMPORTANCE The development of broad-spectrum SARS-CoV-2 vaccines will reduce the global economic and public health stress from the COVID-19 pandemic. The use of conserved T-cell epitopes in combination with spike antigen that induce humoral and cellular immune responses simultaneously may be a promising strategy to further enhance the broad spectrum of COVID-19 vaccine candidates. Moreover, this research suggests that the combined vaccination strategies have the ability to induce both effective systemic and mucosal immunity, which may represent promising strategies for maximizing the protective efficacy of respiratory virus vaccines.

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Vaccines for Respiratory Viruses—COVID and Beyond

Recent Advances in Respiratory Immunization: A Focus on COVID-19 Vaccines

Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

Global progress in clinical research on human respiratory syncytial virus vaccines

Viral-vectored respiratory mucosal vaccine strategies

Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants

Advances in the Design and Development of SARS-CoV-2 Vaccines

A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections

A Multi-Antigen Vaccinia Vaccine Broadly Protected Mice Against SARS-CoV-2 and Influenza A Virus While Also Targeting SARS-CoV-1 and MERS-CoV

Rational Development of a Combined Mrna Vaccine Against COVID-19 and Influenza

Progress in the development of virus-like particle vaccines against respiratory viruses

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic

Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review

Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19

Broad-spectrum pan-genus and pan-family virus vaccines

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

Advances in virus-like particle-based SARS-CoV-2 vaccines

Recent Advances in Vaccine Development of Severe Acute Respiratory Syndrome Coronavirus 2

Advancement in the development of mRNA‐based vaccines for respiratory viruses

Nanoparticle-Based Vaccines Against Respiratory Viruses